MedTrace Logo

Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease

NCT03399175 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-07

No results posted yet for this study

Summary

This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subclinical signs of disease activity added with electroretinogram exams, through predefined intervals, will be evaluated through a minimum 12-month follow-up.

Conditions

  • Vogt Koyanagi Harada Disease

Interventions

DRUG

Early high-dose corticosteroid and immunosuppressive therapy

Early high-dose corticosteroid and immunosuppressive therapy

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Joyce H Yamamoto, MD · University of Sao Paulo School of Medicine Ophthalmology

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-23
Primary Completion
2023-05-18
Completion
2028-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03399175 on ClinicalTrials.gov